Angiogenesis has been proven to play an important role in the progression of hepatocellular carcinoma (HCC). However, the molecular mechanism underlying HCC angiogenesis is not well understood. In this study, Prospero-related homeobox 1 (PROX1) was identified as a novel proangiogenic factor in HCC cell lines and tissues. A strong positive correlation was found between the levels of PROX1 and microvessel density in HCC tissues. Knockdown of PROX1 expression in HCC cells significantly inhibited the in vitro capillary tube formation by human vascular endothelial cells and in vivo angiogenesis of HCC, while overexpression of PROX1 in HCC cells induced the opposite effects. PROX1 and nuclear factor jB p65 expression levels were positively correlated in both HCC tissues and cell lines. PROX1 enhances the nuclear accumulation of p65 and stabilizes p65 by recruiting ubiquitin-specific protease 7 to prevent p65 ubiquitination. Consequently, PROX1 activated nuclear factor jB signaling and selectively promoted expression of the proangiogenic interleukin-8 (IL-8) by epigenetically stimulating the IL-8 promoter. Finally, progression of high PROX1 expression HCC in tumor xenograft mice could be effectively contained by an anti-IL-8 monoclonal antibody. Conclusions: We have identified PROX1 as a crucial promoter of HCC angiogenesis; our study provides an insight into PROX1's function in HCC progression and the potential therapeutic application of anti-IL-8 antibody in high PROX1 expression HCC patients. (HEPATOLOGY 2017;66:1894-1909).
H epatocellular carcinoma (HCC) is one of the most common malignancies worldwide and the third leading cause of death from cancers. (1, 2) HCC has a very poor prognosis, owing to its high potential for vascular invasion, metastasis, and postoperative recurrence. (3) Angiogenesis is well recognized as a hallmark of various malignancies including HCC, usually induced early during the multistage development of invasive cancers both in animal models and in humans. HCC is a kind of hypervascular malignancy with a high level of neovascularization (4) (5) (6) (7) ; however, the molecular mechanism underlying HCC angiogenesis is poorly understood.
Nuclear factor jB (NF-jB) is an important and well-studied transcription factor which is involved in the regulation of angiogenesis. The dominant cellular Abbreviations: CD, cluster of differentiation; cDNA, complementary DNA; co-IP, coimmunoprecipitation; CTF, capillary tube formation; HA, hemagglutinin; HCC, hepatocellular carcinoma; HUVEC, human vascular endothelial cell; IgG, immunoglobulin G; IHC, immunohistochemistry; IL, interleukin; mAb, monoclonal antibody; MVD, microvessel density; NF-jB, nuclear factor jB; PROX1, Prospero-related homeobox 1; Scr, scrambled; SILAC, stable isotope labeling with amino acids in cell culture; siRNA, small interfering RNA; USP7, ubiquitin-specific protease 7; VEGF, vascular endothelial growth factor.
NF-jB is a heterodimer of p50 and p65 subunits. NFjB is translocated into the nucleus in response to various stimuli and activates the expression of proangiogenic genes such as vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), and IL-8. (8, 9) Termination of NF-jB activity requires the ubiquitination and proteasomal degradation of nuclear p65. (10, 11) Aberrant activation of NF-jB signaling has been found in many cancers including HCC. (12) (13) (14) (15) (16) It is uncertain if and how aberrant activation of NF-jB signaling contributes to HCC angiogenesis. The factor(s) that induces this aberrant activation also remains elusive.
Prospero-related homeobox 1 (PROX1) is a regulator of the development of multiple organs and tissues including the central nervous system, heart, eye, lymphatic vessels, pancreas, and liver. (17) (18) (19) (20) (21) (22) Homozygous PROX1 knockout mice are embryonic lethal due to multiple developmental defects. However, the relationship between PROX1 and cancer development is complex, and the functional role and mechanism of PROX1 involved in tumor progression are largely unclear.
In this study, we identified PROX1 as an important promoter of HCC angiogenesis. Levels of PROX1 were positively correlated with microvessel density (MVD) in HCC tissues. PROX1 was demonstrated to promote HCC angiogenesis in both in vitro and in vivo assays. PROX1 could enhance the nuclear accumulation and stabilization of NF-jB p65 by recruiting the deubiquitinase ubiquitin-specific protease 7 (USP7) to inhibit p65 ubiquitination. Consequently, PROX1 was able to activate NF-jB signaling and selectively promote expression of the proangiogenic IL-8. And an anti-IL-8 monoclonal antibody (mAb) significantly inhibited the tumor progression of nude mouse models bearing high PROX1 expression HCC cells.
Materials and Methods

CLINICAL SAMPLES
Tumor specimens were collected during surgical resection on patients treated for HCC. The study contained 178 HCC patients assigned randomly by computer. None of the patients received any preoperative cancer treatment. Use of HCC specimens was approved by the ethics committee of Fudan University.
PLASMIDS
Plasmids were constructed as described. (23) Flagtagged full-length and truncated PROX1 and p65 complementary DNAs (cDNAs) and hemagglutinin (HA)-tagged ubiquitin cDNA were cloned in pcDNA3 (Invitrogen, Carlsbad, CA). The NF-jB responsive reporter was constructed in pGL2-Basic (Promega, Madison, WI). For lentivirus-mediated expression of PROX1, Flag-tagged PROX1 cDNA was inserted in pWPI.1 (Addgene plasmid 12254). For lentivirus-mediated RNA interference of PROX1 expression, DNA fragments encoding the hairpin precursors for si259 (5 0 -TTTCCAGGAGCAACCA  TAATT-3 0 , corresponding to nucleotides 259-279 of the PROX1 open reading frame) and si1646 (5 0 -GGCTCTCCTTGTCGCTCATAA-3 0 , corresponding to nucleotides 1646-1666 of the PROX1 open reading frame) were inserted in pLKO.1 TRC (Addgene plasmid 10879). A scrambled small interfering RNA (siRNA) precursor (Scr) of similar GC content to si259 and si1646 but of no sequence identity with PROX1 was used as a negative control.
ARTICLE INFORMATION:
CELL LINES, TRANSFECTION, AND LENTIVIRUS PREPARATION
Cell culture, transfection and lentivirus preparation were carried out as described. (23) The construction of BEL-7402-Mock, BEL-7402-PROX1, MHCC-97H-Scr, and MHCC-97H-si1646 cells has been described. (23) 
LUCIFERASE REPORTER ASSAYS
Luciferase reporter assays were performed using the Dual Luciferase Report Assay System (Promega) according to the manufacturer's instruction.
CAPILLARY TUBE FORMATION ASSAYS
Each well of a 96-well culture plate was coated with 50 lL of Matrigel (BD Biosciences, San Jose, CA) for 30 minutes at 378C and then seeded with 3 3 10 4 human vascular endothelial cells (HUVECs). Media were collected from cultures of BEL-7402-Mock, BEL-7402-PROX1, MHCC-97H-Scr, and MHCC-97H-si1646 cells. Each well of HUVECs was incubated with 100 lL of the above medium for 6-8 hours. Capillary tube formation (CTF) was examined under an inverted microscope, and images were captured. The total tube numbers from three different fields were measured.
RNA ISOLATION AND QUANTITATIVE REAL-TIME PCR
Total cellular RNA was extracted using TRIzol Reagent (Invitrogen), and reverse-transcription was performed using the PrimeScript RT reagent Kit (TaKaRa, Dalian, China) according to the manufacturer's instructions. Aliquots of cDNA were used for quantitative real-time PCR using SYBRPremix Ex Taq (TaKaRa). PCRs were done in triplicate with the following conditions and repeated at least three times: 958C/30 seconds, 40 cycles of 958C/5 seconds, 608C/ 15 seconds, and 728C/10 seconds on an MXP3000 cycler (Stratagene, La Jolla, CA). The following primer pairs were used: IL-6-f/IL-6-r, GTGAAAGCAGCA AAGAGGCACTGG/CAGGCAAGTCTCCTCA TTGAATCC; IL-8-f/IL-8-r, CTGTGTGAAGGT GCAGTTTTGCC/CGCAGTGTGGTCCACTC TCAATC; VEGF-f/VEGF-r, CATCACCATGCA GATTATGCG/CTATCTTTCTTTGGTCTGCA TTCAC; b-actin-f/b-actin-r, TCCCTGGAGAA GAGCTACG/GTAGTTTCGTGGATGCCACA. Relative mRNA levels were calculated using the 2DDCt method with b-actin as the control and expressed as 2 2DDCt .
IMMUNOPRECIPITATION, COIMMUNOPRECIPITATION, AND SILAC-BASED MASS SPECTROMETRY
Stable isotope labeling with amino acids in cell culture (SILAC)-based mass spectrometry was carried out as described. (24) Normal and Lys8/Arg10-labeled HEK293T cells were transfected with pcDNA3-Flag-PROX1 and empty vector, respectively. A 1:1 mixture of the lysates from the two types of cells was cleared by centrifugation at 12,000g and then loaded onto radio immunoprecipitation assay-equilibrated M2 anti-Flag mAb agarose beads (Sigma, St. Louis, MO). Beads were washed five times with radio immunoprecipitation assay buffer for 5 minutes each, boiled in loading buffer, and resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by silver staining.
Coimmunoprecipitation (co-IP) was performed with the cell lysate precleared through centrifugation at 12,000g for 10 minutes. Flag-PROX1 and Flag-p65 were precipitated as described above, whereas endogenous PROX1 in Huh7 cells was precipitated using the anti-PROX1 polyclonal antibody (Upstate)-conjugated protein A/G agarose beads (GE Healthcare, Chicago, IL). Beads were washed with radio immunoprecipitation assay buffer, boiled in loading buffer, and resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. p65 and USP7 in PROX1-associated proteins were detected by antibodies against p65 (Santa Cruz) and USP7 (Abcam), respectively.
CHROMATIN IMMUNOPRECIPITATION
Anti-H3K9me3 (Abcam), anti-H3K4me3 (Abcam), and anti-AcH3 (Cell Signaling Technology, Danvers, MA) mAbs were used to immunoprecipitate sonicated chromatins prepared from BEL-7402-MOCK, BEL-7402-PROX1, MHCC-97H-SCR, or MHCC-97H-si1646 cells. Precipitation with preimmune immunoglobulin G (IgG) was used for specificity control. Five percent of each postsonication sample was saved as the input control. DNA extracted from precipitated chromatins or the input was quantitated using quantitative real-time PCR in triplicate with the primers for the IL-6 and IL-8 promoters (IL-6p-f/IL-6p-r, CCCT CACCCTCCAACAAAG/CGAGGGCAGAATGA GCCTC; IL-8p-f/IL-8p-r, GGGCCATCAGTTGC AAATC/GCTTGTGTGCTCTGCTGTCTC 
IMMUNOHISTOCHEMISTRY
Immunohistochemical (IHC) staining was performed as described. (25) Primary antibodies included anti-PROX1 polyclonal antibody (1:100; Proteintech), anti-p65 mAb (1:200; Santa Cruz), anti-cluster of differentiation 31 (CD31) mAb (1:100; Abcam), anti-CD34 mAb (1:100; Abcam), and anti-IL-8 mAb (1:100; Abcam). Signals were detected using Envision-plus detection system (EnVision1 horseradish peroxidase, mouse; Dako, Carpinteria, CA) and visualized following incubation with 3,3 0 -diaminobenzidine. Negative controls were treated identically except without primary antibodies.
TUMOR XENOGRAFT MOUSE MODELS AND ANTI-IL-8 mAb TREATMENT
Animal care and experimental protocols were approved by the Animal Ethics Committee of Shanghai Medical College, Fudan University (permit 20101201-001). Tumor xenograft mouse models were established as described. (23, 26) For anti-IL-8 mAb treatment, BEL-7402-MOCK and BEL-7402-PROX1 cells (5.0 3 10 6 cells/mouse) were subcutaneously implanted into the right flanks of nude mice. The BEL-7402-PROX1 group was then randomly divided into two subgroups. From the seventh day after implantation, the mice of one subgroup were treated with anti-IL-8 mAb (10 lg, twice a week for 3 weeks), and the other subgroup was treated with only the isotype-matched IgG. Tumor samples were then collected for further analysis.
STATISTICAL ANALYSIS
The Pearson v 2 test or Fisher's exact test was used to compare qualitative variables and the Student t test for quantitative variables. All statistical tests were twosided. P < 0.05 was considered statistically significant.
Results
EXPRESSION LEVELS OF PROX1 ARE POSITIVELY CORRELATED WITH MVD IN HCC TISSUES
We first detected the expression levels of PROX1 and CD34 in tumor specimens from 178 HCC patients by IHC staining, to investigate the correlation between PROX1 levels and MVD in HCCs. These patients were divided into two groups, high-PROX1 group (PROX1_high, n 5 72 cases) and low-PROX1 group (PROX1_low, n 5 106 cases) based on the PROX1 expression levels. Strong CD34 staining was observed in 91.7% (66/72) of the PROX1_high group, which is much greater in comparison to the 30.2% (32/106) of the PROX1_low group (Fig. 1A, left  panel) . A more advanced MVD was manifest in the PROX1_high group (Fig. 1A, right panel) . The mean MVD level in the PROX1_high group was significantly higher than that of the PROX1_low group (Fig.  1B) . There was a strong positive correlation between the levels of PROX1 and MVD (r 5 0.6418, P < 0.001) (Fig. 1C) .
Moreover, strong staining for IL-8, an important inducer of tumor angiogenesis, was observed in 88.9% (64/72) of the PROX1_high group in comparison to 18.9% (20/106) of the PROX1_low group, and a strong positive correlation was demonstrated between the levels of PROX1 and IL-8 in HCC tissues (r 5 0.678, P < 0.001) (Fig. 1D ).
PROX1 PROMOTES HCC ANGIOGENESIS IN VITRO AND IN VIVO
The level of PROX1 varied greatly in common HCC cell lines. It was barely detectable in BEL-7402 cells, moderate in Huh7 cells, and abundant in MHCC-97H cells. (23) We modified the PROX1 expression in the two representative HCC cell lines, overexpressing exogenous PROX1 in BEL-7402 cells by transduction with the PROX1-expressing lentivirus (BEL-7402-PROX1) or knocking down PROX1 expression in MHCC-97H cells with the lentivirus expressing PROX1 siRNA (si1646) precursor (MHCC-97H-si1646). We collected the culture media of these infected cells and their corresponding controls (BEL-7402-MOCK and MHCC-97H-SCR). We then cultured HUVECs with these media and evaluated CTF by HUVECs. The culture medium of the BEL-7402-PROX1 cells was more potent at inducing CTF by HUVECs compared with that from the BEL-7402-MOCK cells (Fig. 2A) . In contrast, the culture medium of MHCC-97H-si1646 cells was less effective at stimulating CTF by HUVECs than that of its control (Fig. 2B) .
The above cells were further implanted subcutaneously into nude mice to evaluate their influence on in vivo angiogenesis. Four weeks after implantation, tumor tissues were obtained, sectioned, and stained for PROX1 and CD31 to demonstrate the MVD. Markedly higher levels of MVD were observed in the tumor tissues of BEL-7402-PROX1 cells than with BEL-7402-MOCK cells (Fig. 2C) . On the other hand, much lower MVD was detected in the tumors of MHCC-97H-si1646 cells compared with MHCC-97H-SCR cells (Fig. 2D) . These results provide both in vitro and in vivo support that PROX1 is able to promote HCC angiogenesis.
PROX1 FUNCTIONS AS AN ANGIOGENESIS PROMOTER THROUGH INTERACTING WITH NF-jB p65
To further elucidate the molecular mechanism underlying the promotion effects of PROX1 on HCC angiogenesis, we performed co-IP and SILAC-based mass spectrometry to identify the PROX1-associated proteins. NF-jB p65 was identified as one of the proteins that were associated the PROX1 function (Fig.  3A) . The interaction of endogenous p65 with PROX1 in MHCC-97H and Huh7 cells or with FLAG-PROX1 in HEK293T cells was verified using co-IP ( Fig. 3B; Supporting Fig. S1A ). Moreover, endogenous p65 could be detected to colocalize with PROX1 in MHCC-97H cells or with EGFP-PROX1 in Huh7 cells ( Fig. 3C; Supporting Fig. S1B) .
To map the PROX1-interacting region in p65, we constructed several expression plasmids for FLAGtagged truncated p65. Each was cotransfected together with the PROX1 expression plasmid into HEK293T cells. Co-IP was performed with the anti-FLAG mAb, and coprecipitated PROX1 was detected by an anti-PROX1 polyclonal antibody. The region spanning residues 1-306 of p65 was required for the interaction with PROX1 (Fig. 3D) . Reciprocally, several FLAG-tagged truncated PROX1s were expressed in HEK293T cells, and co-IP was carried out as described above using an anti-p65 polyclonal antibody to detect the coprecipitated p65. The results suggest that the N-terminal two thirds (amino acids 1-570) of PROX1 is involved in the interaction with p65 (Fig. 3E) .
EXPRESSION LEVELS OF PROX1 ARE POSITIVELY CORRELATED WITH p65 IN HCC
There was an obvious increase in the level of p65 in HEK293T cells upon PROX1 overexpression (Fig. 3B) . Therefore, we analyzed the correlation between the levels of PROX1 and p65 in tumor tissues from the aforementioned HCC cases. Strong p65 staining was observed in 86.1% (62/72) of the PROX1_high group compared with 41.5% (44/106) in the PROX1_low group (Supporting Fig. S2 ), and a positive correlation was found between the levels of PROX1 and p65 in HCC tissues (r 5 0.440, P < 0.001). Consistent with this clinical observation, compared with the control cells, the level of p65 was increased in PROX1-overexpressing BEL-7402, Huh7, and HEK293T cells ( Fig.  4A; Supporting Fig. S3A ) but significantly decreased in PROX1 knockdown MHCC-97H and Huh7 cells (Fig. 4B ).
PROX1 PROMOTES NUCLEAR ACCUMULATION OF p65 IN HCC CELLS
Nuclear translocation of p65 is a hallmark of the activation of NF-jB signaling. Notably, all 62 HCC samples with high levels of both PROX1 and p65 displayed strong nuclear p65 signals (Supporting Fig. S2 , left panel). Using cell fractionation and western blot, we found that both the cytoplasmic and nuclear levels of p65 were significantly increased upon PROX1 overexpression in BEL-7402 and Huh7 cells (Fig. 4C) , while these were decreased in PROX1 knockdown MHCC-97H and Huh7 cells (Fig. 4D) . Furthermore, obviously stronger nuclear signals of p65 were detected in BEL-7402 and Huh7 cells when the expression of exogenous PROX1 was induced (Fig. 4E) , but the nuclear signals of p65 were significantly decreased in PROX1 knockdown MHCC-97H cells (Fig. 4F) . These data indicate that PROX1 is able to promote nuclear accumulation of p65 in HCC cells. 6 cells/mouse, n 5 6 mice/group). MVD in tumor tissues was evaluated based on staining for CD31. Significant differences were determined using Student t test, *P < 0.05, **P < 0.01, ***P < 0.001. 
PROX1 IMPROVES THE PROTEIN STABILITY OF p65
The PROX1-mediated elevation in p65 level might be due to an enhanced stability of p65 protein. To assess this possibility, we examined the level of p65 at selected time points after HCC cells were treated with the translation inhibitor cycloheximide. The half-life of p65 was substantially prolonged in PROX1-overexpressing BEL-7402 cells (Fig. 5A ) but markedly shortened in PROX1 knockdown MHCC-97H cells (Fig. 5B) . Moreover, when BEL-7402 cells or Huh7 cells were cotransfected with a fixed amount of the expression plasmid of FLAG-p65 together with an increasing dose of the expression plasmid for HAtagged PROX1 (HA-PROX1), the level of FLAGp65 increased progressively with the gradual increase in expression of HA-PROX1 (Fig. 5C ). Because the expression of FLAG-p65 was not controlled by HA-PROX1 (data not shown), these results suggest that FLAG-p65 is stabilized by HA-PROX1.
PROX1 RECRUITS USP7 TO INHIBIT p65 UBIQUITINATION
Because p65 is degraded through a ubiquitindependent mechanism, we wonder if PROX1 is able to inhibit p65 ubiquitination. USP7, which has been demonstrated to promote p65 stability by acting as a deubiquitinase to inhibit p65 ubiquitination, (27) was identified by mass spectrometry (Supporting Fig. S4 ). We then investigated if PROX1 could recruit USP7 to p65. Endogenous USP7 in HEK293T cells could be coprecipitated with FLAG-PROX1 in co-IP assays (Fig. 5D) . USP7 was also found to colocalize with PROX1 in MHCC-97H cells or with EGFP-PROX1 in Huh7 cells ( Fig. 5E; Supporting Fig. S5A) . Moreover, the amount of USP7 coprecipitated with p65 increased in BEL-7402 cells upon PROX1 overexpression (Fig. 5F ), while it diminished in PROX1 knockdown MHCC-97H cells (Fig. 5G) . These results suggest that PROX1 recruits USP7 to p65 through its association with USP7. We further examined the level of p65 ubiquitination. BEL-7402 or MHCC-97H cells were cotransfected with the expression plasmids for HA-ubiquitin, FLAG-p65, and PROX1 or PROX1 short hairpin RNA. Co-IP assays were conducted using the anti-FLAG mAb, followed by detection of the ubiquitin-conjugated FLAG-p65 using the anti-HA mAb. Upon PROX1 overexpression, the quantity of the ubiquitin-conjugated FLAG-p65 was markedly diminished, and there was a concurrent increase in the amount of USP7 coprecipitated with FLAG-p65 (Supporting Fig. S5B ). In contrast, knockdown of PROX1 expression resulted in a much higher level of p65 polyubiquitylation and a reduction in the amount of USP7 coprecipitated with FLAGp65 (Supporting Fig. S5C) . Moreover, the level of endogenous ubiquitin-conjugated p65 markedly diminished in BEL-7402 cells upon PROX1 overexpression (Fig. 5H) , while it increased in PROX1 knockdown MHCC-97H cells (Fig. 5I) . These results indicate that PROX1 recruits USP7 to inhibit p65 ubiquitination.
PROX1 ACTIVATES NF-jB SIGNALING AND SELECTIVELY UP-REGULATES THE EXPRESSION OF IL-8
We next examined whether PROX1 could activate the universal NF-jB-responsive promoter (NF-jB reporter), which is commonly used as an indicator of NF-jB signaling activity. Indeed, NF-jB reporter expression was activated by PROX1 overexpression in BEL-7402, Huh7, and HEK293T cells ( Fig. 6A;  Supporting Fig. S3A ,C) but repressed in PROX1 knockdown MHCC-97H and Huh7 cells ( Fig. 6B;  Supporting Fig. S3D ). We then determined which proangiogenic NF-jB target gene(s) (IL-8, IL-6, and VEGF) would be responsive to PROX1-mediated activation. The mRNA levels of IL-8, IL-6, and VEGF in PROX1-overexpressing BEL-7402 cells increased by 9.0-fold, 1.2-fold, and 1.4-fold, respectively, in PROX1-overexpressing BEL-7402 cells (Fig. 6C ). Accordingly, the mean level of IL-8 in the culture medium of BEL-7402-PROX1 cells (0.66 ng/mL) was about two times that of the control cells (0.23 ng/ mL) (Fig. 6E, upper panel) . These mRNA levels in PROX1 knockdown MHCC-97H cells decreased by 80%, 10%, and 20%, respectively, in PROX1 knockdown MHCC-97H cells (Fig. 6D) ; and the mean level of IL-8 in the culture medium of MHCC-97H-si1646 (0.13 ng/mL) was about 25% of that of the control cells (0.52 ng/mL) (Fig. 6E, lower panel) . Next, overexpression of the amino acid 1-570 fragment of PROX1 involved in the interaction with p65 did not up-regulate IL-8 expression in BEL-7402 and Huh7 cells (Supporting Fig. S6 ), suggesting that the interaction with p65 alone is not sufficient to mediate PROX1's promotion of IL-8 expression. Furthermore, 0 ,6-diamidino-2-phenylindole. (F,G) Co-IP was carried out using anti-p65 mAb with rabbit IgG as nonspecific control. Co-IP USP7 was detected using anti-USP antibody. (H,I) Co-IP assays were conducted with the anti-p65 mAb, followed by detection of the ubiquitin-conjugated p65 with the anti-ubiquitin antibody. Significant differences were determined using Student t test, *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: CHX, cycloheximide; DAPI, 4 0 ,6-diamidino-2-phenylindole; IB, immunoblot; IP, immunoprecipitation; Ub, ubiquitin. (G,H) Precipitated IL-8 promoter segments were measured using quantitative real-time PCR against 5% input. Mean 6 standard deviation from three independent experiments is presented. Significant differences were determined using Student's t test, *P < 0.05, **P < 0.01, ***P < 0.001. IL-8 mAb (100 ng/mL) in the medium from the BEL-7402-PROX1 cell culture could abrogate the medium's potency at stimulating CTF by HUVECs (Fig. 6F, upper panel) . In contrast, supplementation of the medium from the MHCC-97H-si1646 cell culture with 0.3 ng/mL of recombinant IL-8 could restore the medium's activity in promoting CTF by HUVECs (Fig. 6F, lower panel) . We analyzed the correlation between the levels of PROX1 and VEGF in tumor tissues from the aforementioned HCC cases. Strong VEGF staining was observed in 55.6% ( 
EFFECTS OF PROX1 ON THE ACTIVITY OF THE IL-8 PROMOTER
We examined the epigenetic changes on the promoters of IL-8 and IL-6 genes in response to PROX1 expression using chromatin immunoprecipitation assays with anti-H3K4me3, anti-H3K9me3, and antiAcH3 polyclonal antibodies. Transcriptional activation is often associated with a reduced trimethylation of H3K9 and an increased trimethylation of H3K4 and acetylation of H3. (28) (29) (30) (31) (32) The H3K4me3 level on the IL-8 promoter was significantly increased in PROX1-overexpressing BEL-7402 cells, while it was markedly decreased in PROX1 knockdown MHCC-97H cells (Fig. 6G) , which was the reverse of H3K9me3 levels (Fig. 6H) . In contrast, neither the levels of H3K4me3 and H3K9me3 on the IL-6 promoter nor the AcH3 levels on the IL-6 and IL-8 promoters were affected by the changes of PROX1 expression in these cells (Supporting Figs. S9 and S10 ). These data suggest that PROX1 is able to epigenetically activate the IL-8 promoter.
IL-8 IS A POTENTIAL THERAPEUTIC TARGET FOR HCC WITH A HIGH LEVEL OF PROX1
We finally assessed the potential of IL-8 as a therapeutic target for HCC. BEL-7402 cells were used to establish subcutaneous implantation models in nude mice. Mice implanted with BEL-7402-PROX1 cells were randomly divided into two subgroups, which were treated with anti-IL-8 mAb or the matched isotype IgG on the seventh day after implantation, respectively. Tumor tissues were obtained and examined using IHC staining for CD31 at the twenty-first day after the first antibody injection. The results showed that the mean level of MVD markedly decreased in the anti-IL-8 mAb treatment group compared with that in the controls (Fig. 7A,B) . Moreover, anti-IL-8 mAb treatment was able to significantly increase the overall survival of mice (Fig. 7C) . Next, we also used MHCC-97H cells that express high levels of endogenous PROX1 to establish subcutaneous implantation models. The results showed that the tumor weight and the mean level of MVD markedly decreased in the anti-IL-8 mAb treatment group compared with those in the control group (Fig. 7D,E) . These results indicate that the anti-IL-8 mAb might be a promising choice for the treatment of HCC with a high level of PROX1.
Discussion
PROX1 has been demonstrated to play an important role in the development of human cancers. (33) It exhibits tumor suppressor or oncogenic activity depending on cancer type, which suggests that the functional roles of PROX1 in cancer development are complex and depend on tissue and cellular context. Consistent with PROX1's function in liver development, we previously demonstrated that high levels of PROX1 in HCC strongly promote tumor growth and metastasis. (23, 26) However, the underlying molecular mechanism is not well understood. In the present study, from investigations on clinical samples and cell lines, we provide both in vitro and in vivo evidence suggesting a function of PROX1 in promoting HCC angiogenesis. Taken together, our findings have validated PROX1's importance in HCC development. Whether PROX1 is involved in the angiogenesis of other cancer types awaits further in-depth studies.
